Evidence map›Paper›PMID 42724566›Full record

ArticleJournal of thoracic disease2026

Prevalence and outcomes of pleuroparenchymal fibroelastosis in patients with non-tuberculous mycobacterial pulmonary disease: a French retrospective cohort study.

Maïwenn Poidevin-Belkadi, Samia Boussouar, Nicolas Veziris, Maxens Decavele, Capucine Morelot-Panzini, Jacques Cadranel, Thomas Maitre, Christophe Cracco

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maïwenn Poidevin-BelkadiService de Pneumologie (Département R3S), Site Pitié Salpêtrière, APHP-6 Sorbonne Université, Paris, France.ORCID https://orcid.org/0009-0002-9554-8927
Samia BoussouarImagerie Cardiovasculaire et Thoracique (ICT), Pitié-Salpêtrière, Sorbonne Université, AP-HP, Paris, France.
Nicolas VezirisCentre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, INSERM 1135, Paris, France.
Maxens DecaveleService de Médecine Intensive-Réanimation (Département R3S), Site Pitié-Salpêtrière, APHP Sorbonne Université, Paris, France.
Capucine Morelot-PanziniService de Pneumologie (Département R3S), Site Pitié Salpêtrière, APHP-6 Sorbonne Université, Paris, France.
Jacques CadranelService de Pneumologie et d'Oncologie Thoracique et Centre Constitutifs Maladies Pulmonaires Rares, Hôpital Tenon, AP-HP Sorbonne Université and OrphaLung, Centre National Constitutif de Référence des Maladies Pulmonaires Rares, Paris, France.
Thomas MaitreCentre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, INSERM 1135, Paris, France.
Christophe CraccoService de Pneumologie (Département R3S), Site Pitié Salpêtrière, APHP-6 Sorbonne Université, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pleuroparenchymal fibroelastosis (PPFE) is a recently described interstitial lung disease associated with multiple diseases. Japanese studies found an association between PPFE and non-tuberculous mycobacterial pulmonary disease (NTM-PD), but no study has been conducted in Europe. We aimed to assess in France the prevalence of PPFE among patients with NTM-PD, and to look for risk factors of PPFE and mortality. Method: We conducted a retrospective cohort study in two French hospitals from January 1, 2020 to March 31, 2022. NTM-PD patients were included if they had at least one chest high-resolution computed tomography (HRCT) scan available, to identify the presence or the occurrence of radiological patterns of PPFE based on established criteria. Risk factors for PPFE and five-year mortality were assessed using univariate and multivariate analyses. Results: A total of 101 patients were included, PPFE was identified in 14 patients (13.9%) and was associated with a lower body mass index (BMI) at diagnosis [odds ratio (OR) 21.4, 95% confidence interval (CI): 3.5-415.3 for BMI <18 kg/m² with PPFE, P<0.001] in multivariate exploratory analysis. Seventy patients had a minimum of two chest HRCT scans spaced by at least 3 years. Among them, 10 had PPFE: 8 at NTM-PD diagnosis, and 1 PPFE developing from pleural caps 9 years later. Five-year mortality could be studied for 71 patients. PPFE was associated with 5-year mortality (OR 6.3, 95% CI: 1.3-29.9, P=0.02) in multivariate exploratory analysis. Conclusions: PPFE is frequently observed among patients with NTM-PD, and seems to be associated with a lower BMI and the 5-year mortality, supporting its systematic screening in this population.

Indexed as

interstitial lung disease (ILD)non-tuberculous mycobacterial pulmonary infection (NTM pulmonary infection)pleural capPleuroparenchymal fibroelastosis (PPFE)

Identifiers

PMID42724566
PMCPMC13559321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.